MetaVia Inc. (MTVA)
Nasdaq · Healthcare · Biotechnology
$1.540.00%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $10.2M
- 52-week range
- $0.966 – $14.85
- 52-week change
- −86.79%
- EPS (trailing)
- −$3.65
Fiscal year to Dec 2025
- Net income
- −$13.0M
- Diluted EPS
- −$7.35
- Free cash flow
- −$15.7M
From the company’s annual report on SEC EDGAR.
About MetaVia Inc.
MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in Phase 1 trial for the treatment of obesity. Its therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. The company has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and Dong-A ST, a sole manufacturer for the production of DA-1241 and DA-1726.
Headquarters: Cambridge, United States · 8 employees · metaviatx.com